{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:15:57Z","timestamp":1777907757486,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Pharmacopsychiatry"],"abstract":"<jats:p>In a systematic clinical study, indluding four uncontrolled clinical trials with\npsychiatric patients belonging to four different diagnostic groups, trazodone, the first triazolopyridine\ncompound subjected to clinical investigation, was found to be a therapeutically\neffective psychoactive drug. Since the most consistent therapeutic action of trazodone\nwas seen to be in the depressive syndrome, i.e., Guilt Feelings, Motor Retardation and\nDepressive Mood, it was suggested that trazodone has a therapeutic effect on depressive\nsymptoms whether they occur in depression, neurosis, organic brain syndrome or schizophrenia.<\/jats:p>","DOI":"10.1159\/000468167","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:19:51Z","timestamp":1502471991000},"page":"42-53","source":"Crossref","is-referenced-by-count":5,"title":["Psychotherapeutic Profile of a New Psychoactive Drug\nTrazodone (AF-1161)"],"prefix":"10.1159","author":[{"given":"Heinz E.","family":"Lehmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Ban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["International Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000468167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:46:23Z","timestamp":1777643183000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000468167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000468167","archive":["Portico"],"relation":{},"ISSN":["0020-8272","2504-2580"],"issn-type":[{"value":"0020-8272","type":"print"},{"value":"2504-2580","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}